William Blair analyst Myles Minter has maintained their bullish stance on NBIX stock, giving a Buy rating on December 19.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Myles Minter has given his Buy rating due to a combination of factors that outweigh the recent clinical setback. Although the Phase III trial of valbenazine in dyskinetic cerebral palsy failed to reach its main goals, this indication contributed only a small amount to his valuation model, so its removal has little impact on his overall outlook. Even after excluding this program, his refreshed sum-of-the-parts fair value estimate of about $204 per share still represents a substantial upside versus the recent trading price. He emphasizes that the core investment narrative continues to hinge on Neurocrine’s ability to execute commercially and deliver solid performance in 2026.
Minter also highlights the strength and depth of Neurocrine’s pipeline as a key driver of his positive stance. He points to the company’s recent R&D day, which underscored promising late-stage neuropsychiatric programs and early obesity research that could create significant long-term value. In particular, he notes the planned first-half 2026 clinical entry of a novel CRF2 agonist designed to offer GLP-1/GIP-like efficacy with improved tolerability and muscle preservation, as well as upcoming early-safety readouts across the muscarinic agonist portfolio. While he expects 2026 to be relatively quiet in terms of near-term trial readouts, he believes the stage is set for a subsequent period rich in catalysts, supporting his continued bullish view and Buy rating on Neurocrine.
Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, VistaGen Therapeutics, and Biogen. According to TipRanks, Minter has an average return of 29.5% and a 59.66% success rate on recommended stocks.
In another report released on December 19, Canaccord Genuity also reiterated a Buy rating on the stock with a $164.00 price target.